Luxembourg: ABL licenses HIV treatment patent portfolio to Viralliance

Licensing agreement

Advanced Biological Laboratories (ABL), spun out from the European academic research centre CRP-Santé in Luxembourg, has signed a licence agreement with Delaware, US, corporation Viralliance, granting it nonexclusive and royalty bearing rights to use ABL’s patent portfolio for guiding and ranking the selection of treatment regimens for patients with HIV.

ABL specialises in the molecular biology and clinical outcome predictors of HIV, hepatitis and HPV viruses, and has a strong focus on HIV drug resistance, in particular algorithm-based genotype interpretation systems, the management of sequence and complex integrated clinico-virological databases, and on more advanced genetic analysis tools such as virus subtype characterisation.

ABL owns US patents as well as their foreign equivalents, and is currently in the process of licensing intellectual property to diagnostic manufacturers, therapeutic companies, and diagnostic service providers.

Viralliance is dedicated to optimise drug discovery and patient treatment in the field of infectious disease and cancer. It develops technologies to evaluate in vitro antiviral drug potency. It has developed a HIV phenotypic test which assesses resistance to antiretroviral drugs used to treat HIV to help clinicians administer the most suitable HIV drug to patients.